YGYannick Guilloux

Yannick Guilloux

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yannick Guilloux has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Alpha-Radiotherapy on the Tumor Microenvironment

    by Mathilde Allard, Justine Perrin, Yannick Guilloux, Françoise Kraeber-Bodéré, Michel Chérel, Joëlle Gaschet

  • Impact of Alpha-Radiotherapy on the Tumor Microenvironment

    by Mathilde Allard, Justine Perrin, Yannick Guilloux, Françoise Kraeber-Bodéré, Michel Chérel, Joëlle Gaschet

  • Targeted Alpha Particle Therapy Remodels the Tumor Microenvironment and Improves Efficacy of Immunotherapy

    by Justine Perrin, Marisa Capitao, Mathilde Allard, Nicolas Chouin, Sebastien Gouard, Séverinne Marionneau-Lambot, Cédric Louvet, Emmanuel Donnadieu, Frank Bruchertseifer, Alfred Morgenstern, et al.


  • Open Access

    Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model

    by Marisa Capitao, Justine Perrin, Sylvain Simon, Sébastien Gouard, Nicolas Chouin, Frank Bruchertseifer, Alfred Morgenstern, Latifa Rbah-Vidal, Michel Chérel, Emmanuel Scotet, et al.

    PD-L1 (programmed death-ligand 1, B7-H1, CD274), the ligand for PD-1 inhibitory receptor, is expressed on various tumors, and its expression is correlated with a poor prognosis in melanoma. Anti-PD-L1 mAbs have been developed along with anti-CTLA-4 and anti-PD-1 antibodies for immune checkpoint inhibitor (ICI) therapy, and anti-PD-1 mAbs are now used as first line treatment in melanoma. However, many patients do not respond to ICI therapies, and therefore new treatment alternatives should be developed. Because of its expression on the tumor cells and on immunosuppressive cells within the tumor microenvironment, PD-L1 represents an interesting target for targeted alpha-particle therapy (TAT). We developed a TAT approach in a human melanoma xenograft model that stably expresses PD-L1 using a 213Bi-anti-human-PD-L1 mAb. Unlike treatment with unlabeled anti-human-PD-L1 mAb, TAT targeting PD-L1 significantly delayed melanoma tumor growth and improved animal survival. A slight decrease in platelets was observed, but no toxicity on red blood cells, bone marrow, liver or kidney was induced. Anti-tumor efficacy was associated with specific tumor targeting since no therapeutic effect was observed in animals bearing PD-L1 negative melanoma tumors. This study demonstrates that anti-PD-L1 antibodies may be used efficiently for TAT treatment in melanoma.


  • Combining RAIT and Immune-Based Therapies to Overcome Resistance in Cancer?

    by Jean-Baptiste Gorin, Jérémie Ménager, Yannick Guilloux, Jean-François Chatal, Joëlle Gaschet, Michel Chérel

  • Open Access

    Radio-immunothérapie alpha

    by Jérémie Ménager, Jean-Baptiste Gorin, Nolwenn Fichou, Sébastien Gouard, Alfred Morgenstern, Frank Bruchertseifer, François Davodeau, Françoise Kraeber-Bodéré, Michel Chérel, Joëlle Gaschet, et al.

    Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé


  • Open Access

    Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction

    by Jérémie Ménager, Jean-Baptiste Gorin, Catherine Maurel, Lucile Drujont, Sébastien Gouard, Cédric Louvet, Michel Chérel, Alain Faivre-Chauvet, Alfred Morgenstern, Frank Bruchertseifer, et al.

    Ionizing radiation induces direct and indirect killing of cancer cells and for long has been considered as immunosuppressive. However, this concept has evolved over the past few years with the demonstration that irradiation can increase tumor immunogenicity and can actually favor the implementation of an immune response against tumor cells. Adoptive T-cell transfer (ACT) is also used to treat cancer and several studies have shown that the efficacy of this immunotherapy was enhanced when combined with radiation therapy. α-Radioimmunotherapy (α-RIT) is a type of internal radiotherapy which is currently under development to treat disseminated tumors. α-particles are indeed highly efficient to destroy small cluster of cancer cells with minimal impact on surrounding healthy tissues. We thus hypothesized that, in the setting of α-RIT, an immunotherapy like ACT, could benefit from the immune context induced by irradiation. Hence, we decided to further investigate the possibilities to promote an efficient and long-lasting anti-tumor response by combining α-RIT and ACT. To perform such study we set up a multiple myeloma murine model which express the tumor antigen CD138 and ovalbumine (OVA). Then we evaluated the therapeutic efficacy in the mice treated with α-RIT, using an anti-CD138 antibody coupled to bismuth-213, followed by an adoptive transfer of OVA-specific CD8+ T cells (OT-I CD8+ T cells). We observed a significant tumor growth control and an improved survival in the animals treated with the combined treatment. These results demonstrate the efficacy of combining α-RIT and ACT in the MM model we established.


  • Open Access

    Cross-Presentation of Synthetic Long Peptides by Human Dendritic Cells: A Process Dependent on ERAD Component p97/VCP but Not sec61 and/or Derlin-1

    by Jérémie Ménager, Frédéric Ebstein, Romain Oger, Philippe Hulin, Steven Nedellec, Eric Duverger, Andrea Lehmann, Peter-Michael Kloetzel, Francine Jotereau, Yannick Guilloux

    Antitumor vaccination using synthetic long peptides (SLP) is an additional therapeutic strategy currently under development. It aims to activate tumor-specific CD8+ CTL by professional APCs such as DCs. DCs can activate T lymphocytes by MHC class I presentation of exogenous antigens - a process referred to as “cross-presentation”. Until recently, the intracellular mechanisms involved in cross-presentation of soluble antigens have been unclear. Here, we characterize the cross-presentation pathway of SLP Melan-A16–40 containing the HLA-A2-restricted epitope26–35 (A27L) in human DCs. Using confocal microscopy and specific inhibitors, we show that SLP16–40 is rapidly taken up by DC and follows a classical TAP- and proteasome-dependent cross-presentation pathway. Our data support a role for the ER-associated degradation machinery (ERAD)-related protein p97/VCP in the transport of SLP16–40 from early endosomes to the cytoplasm but formally exclude both sec61 and Derlin-1 as possible retro-translocation channels for cross-presentation. In addition, we show that generation of the Melan-A26–35 peptide from the SLP16–40 was absolutely not influenced by the proteasome subunit composition in DC. Altogether, our findings propose a model for cross-presentation of SLP which tends to enlarge the repertoire of potential candidates for retro-translocation of exogenous antigens to the cytosol.